Topic Briefing

Digital Health

Executive Summary

The FDA is accelerating domestic pharma manufacturing and medical import processing through new PreCheck and ImportShield programs. Hims & Hers halted sales of its compounded oral obesity pill under pressure from the DOJ and FDA, while a review of the administration's new TrumpRx site found nearly 40% of its brand-name drugs have cheaper generic versions elsewhere.

Key Takeaways

  • Stop selling compounded oral GLP-1 drugs: Hims & Hers withdrew its $49/month oral obesity pill after the DOJ and FDA signaled decisive legal action against the mass-marketing of unapproved compounded formulations. Source
  • Prepare for faster medical import processing: The FDA's new ImportShield program consolidated five regional teams into a single operation, increasing processing speed by 66% and saving over 3,300 staff hours per month. Source
  • Deploy digital phenotyping for early mental health screening: A new study found that combining active self-reports with passive smartphone sensor data can predict adolescent mental health risks with 77% accuracy. Source
  • Advise patients to price-check TrumpRx against generics: Analysis of the new administration platform found that 18 of its 43 featured brand-name drugs are cheaper as generics through competitors like GoodRx or Cost Plus Drugs. Source

Key Themes

Major trends and developments identified from this week's coverage

Federal Regulatory Modernization

The FDA is modernizing its operational footprint to speed up domestic manufacturing facility approvals and international product inspections.

3 articles

Administrative Cost Accountability

Regulators and payers are increasing scrutiny on high-margin telehealth segments and revenue cycle management accuracy to lower aggregate spending.

3 articles

Key Players

Top companies, people, and technologies mentioned this week

OpenAI
Company●●●●●

2 articles

Released GPT-5.3-Codex, a specialized coding model integrated into their Codex app. (+1 more)

Google
Company●●●●●

2 articles

Referenced in the Oracle v. Google legal case regarding the protectability of APIs. (+1 more)

Donald Trump
Person●●●●●

2 articles

His administration announced major changes to the federally recommended vaccination schedule for children. (+1 more)

FDA
Company●●●●●

4 articles

Stated it would take decisive steps against companies mass-marketing unapproved compounded GLP-1 drugs. (+3 more)

Robert F. Kennedy Jr.
Person●●●●●

2 articles

Serves as HHS Secretary with a 55% disapproval rating regarding his job performance. (+1 more)

Oracle
Company●●●●●

3 articles

Referenced in the Oracle v. Google legal case regarding the protectability of APIs. (+2 more)

PROSPERO
Technology●●●●●

2 articles

The registry where the systematic review protocol was officially recorded (CRD42024527317). (+1 more)

Centers for Disease Control and Prevention
Company●●●●●

2 articles

Federal agency that provided estimates on the number of Americans who could benefit from PrEP. (+1 more)

Trump administration
Company●●●●●

2 articles

The administration that reduced the number of recommended childhood vaccines for routine use. (+1 more)

Food and Drug Administration
Company●●●●●

2 articles

Mentioned as a related topic of interest in the KFF report. (+1 more)

Regulatory & Policy Updates

Technology & Innovation

Digital phenotyping achieves 77% accuracy for mental health risk prediction

Enables school systems and community clinics to conduct scalable, passive screening for adolescent insomnia and suicidal ideation.

RCT validates 24-minute sleep duration increase via Headspace app

Provides employers with evidence-based data to support mHealth app coverage for workforce wellness programs.

EHR vendors retain 'write' access control as critical IP barrier

Third-party AI developers must still replicate complex application logic to write data back to EHRs, slowing automated clinical documentation.

Market & Competitive Intelligence

Hims & Hers

Partnership

Hims & Hers ceased sales of its compounded oral obesity medication after DOJ and HHS launched an investigation into potential violations of federal law.

ClaimInsight

Partnership

Self-insured employers are increasing oversight of TPA payment integrity to reclaim millions in small, aggregated claim errors under $500.

Magnet Biomedicine / Eric Schmidt

Funding

Magnet Biomedicine appointed Nick Vlahakis as Chief Medical Officer; former Google CEO Eric Schmidt launched a $150 million AI-focused biotech fund.

What to Watch

PreCheck Facility Cohort Selection

Late 2026

The FDA will select an initial cohort of critical drug manufacturing facilities for the PreCheck program in late 2026.

Diagnostic Imaging Standards Feedback

Q1 2026

Stakeholders have 45 days to submit comments on the ASTP/ONC Imaging RFI to shape future EHI exchange standards.

GLP-1 Expansion for Addiction Therapy

2026-2027

Watch for the expansion of GLP-1 clinical trials specifically targeting addiction, following the emergence of new startups in this segment.

Editor's Picks

AI-recommended articles based on relevance and quality

Want personalized briefings?

Kelp creates AI-powered briefings tailored to your specific interests and sources. Get the insights that matter most to you.

Start Your Free Briefing